Investigation of Seroprevalence of Hepatitis B, Hepatitis C and HIV in Hemodialysis Patients

Yıl 2021, Cilt: 11 Sayı: 4, 452 - 455, 31.07.2021

Ahmed Nsangou Rugıyya Samadzade Salih Maçin , Gülperi Çelik , Duygu Fındık

Öz

Aim: Impairments in the immune system of patients undergoing HD cause patients to be more sensitive to infection agents. The purpose of this study; to determine the seroprevalance of HBV, HCV and HIV in patients undergoing hemodialysis treatment.
Materials and Methods: HBsAg, Anti-HBs, Anti-HBc IgM, Anti-HBc IgG, HBV-DNA, Anti-HCV, HCV-RNA and Anti-HIV parameters studied from serum samples of Chronic Kidney Patients (CKD) undergoing hemodialysis treatment at Selçuk University Faculty of Medicine It has been scanned retrospectively for ten years.
Results: HBsAg was determined in 17 (0.40%) of 4155 hemodialysis patients and Anti-HBs was positive in 454 (11.2%). Anti-HCV was detected as positive in 14 (0.33%) serum. HBV-DNA was found to be positive in 13 (76.5%) of HBsAg positive HD patients and in 12 (85.7%) of Anti-HCV positive patients. Anti-HIV antibodies were not detected in any of the serum samples.
Conclusions: The results of our study have shown that proper infection control measures in hemodialysis patients can reduce the contamination of infectious agents. In addition, factors such as vaccination scheme, inoculation site and dose should be selected appropriately, taking into account the immunosuppressive state of the patients.

Anahtar Kelimeler

Hemodialysis, Chronic Kidney Patients, Hepatitis B, Hepatitis C, HIV

Hemodiyaliz Hastalarında Hepatit B, Hepatit C ve HIV Seroprevalansının Araştırılması

Öz

Amaç: Hemodiyaliz (HD) uygulanan hastaların bağışıklık sistemindeki bozulmalar, hastaların enfeksiyon ajanlarına daha duyarlı olmasına neden olur. Bu çalışmanın amacı; hemodiyaliz tedavisi gören hastalarda HBV, HCV ve HIV seroprevalansını belirlemek olmuştur.
Gereç ve Yöntem: Selçuk Üniversitesi Tıp Fakültesin’de hemodiyaliz tedavisi gören Kronik Böbrek Hastalarının (KBH) serum örneklerinden çalışılmış HBsAg, Anti-HBs, Anti-HBc IgM, Anti-HBc IgG, HBV-DNA, Anti-HCV, HCV-.RNA ve Anti-HIV parametrleri on yıl boyunca retrospektif olarak taranmıştır.
Bulgular: 4155 hemodiyaliz hastasının 17'sinde (% 0,40) HBsAg ve 454'ünde ise (% 11,2) Anti-HBs pozitif bulunmuştur. Anti-HCV 14 (% 0.33) hastanın serumunda pozitift olarak saptanmıştır. HBsAg pozitif HD hastalarının 13'ünde (% 76,5) HBV-DNA ve Anti-HCV pozitif hastaların 12'sinde (% 85,7) HCV RNA pozitift olarak belirlenmiştir. Serum örneklerinin hiçbirinde anti-HIV antikorları tespit edilmemiştir.
Sonuç: Çalışma sonuçları, hemodiyaliz hastalarında uygun enfeksiyon kontrol önlemlerinin bulaşıcı ajanların kontaminasyonunu azaltabileceğini göstermiştir. Ayrıca, aşılama şeması, aşılama yeri ve doz gibi faktörler, hastaların immünosupresif durumu dikkate alınarak uygun şekilde seçilmelidir.

Anahtar Kelimeler

Hemodiyaliz, Kronik Böbrek Hastalığı, Hepatit B, Hepatit C, HIV

Kaynakça

• 1. Nissenson AR, Fine RN.Clinical Dialysis. Translation Editor: Akoglu E. Gunes Medical Bookstores, 4th Edition, Ankara 2009: 927-37.
• 2. Mohanty NK, Sahoo KC, Pati S, Sahu AK, Mohanty R. Prevalence of Chronic Kidney Disease in Cuttack District of Odisha, India. Int J Environ Res Public Health 2020;17(2):456.
• 3. Fernando BNTW, Sudeshika TSH, Hettiarachchi TW et al. Evaluation of biochemical profile of Chronic Kidney Disease of uncertain etiology in Sri Lanka. PLoS ONE 2020;15(5):e0232522
• 4. Kalender B, Erdogan MS, Sengul E, Serdengeçti K, Erek E, Yılmaz A. Relationship between nutritional status and dialysis adequacy in hemodialysis patients. Cerrahpasa Med J 2002;33(4):223-30.
• 5. Temiz H, Kaya S, Berekatoglu N, Temiz S, Danis R. Evaluation of HBV, HCV and HIV Seroprevalence and Antibody Response Caused by Hepatitis B Vaccination in Hemodialysis Patients. J Viral Hepat 2013;9(3):140-3.
• 6.Çopur Çiçek A, Sahin OZ, Topaloglu MK, et al. HBsAg,anti-HBs and anti-HCV seroprevalence in hemodialysis patients in Rize province. J Viral Hepat 2013;19(1):15-18.
• 7. Yuksel E, Kaya S, Gunay E, Araç E. HBV, HCV and HIV seroprevalence in hemodialysis patients. Klimik Derg 2019;32(2):165-7.
• 8.Guvenir M, Guler E, Oygar D, Behlul A, Suer K. Evaluating the Prevalence of HBV, HCV, and HIV in Hemodialysis Patients in North Cyprus. Hepat Mon.2019;19(1):e84699.
• 9. Yadegarynia D, Hatamai H, Roodsari SR, Arab-Mazar Z. Seroprevalence of Hepatitis B, C and D Viral Among Hemodialysis Patients in Tehran. Iran J Microbiol 2017; 9 (3):95-9.
• 10. Halle MP, Choukem SP, Kaze FF et al. Hepatitis B, Hepatitis C, and Human Immune deficiency Virus Seroconversion Positivity Rates and Their Potential Risk Factors Among Patients on Maintenance Hemodialysis in Cameroon. Iranian J Kidney Dis 2016;10 (5);304-9.
• 11. Duong CM, Olszyna DP, McLaws ML. Hepatitis B and C Virus Infections Among Patients with End Stage Renal Disease in a Lows-Resourced Hemodialysis Center in Vietnam: A Cross- Sectional Study. BMC Public Health 2015;27(15):1532-39.
• 12. Ozturk Kaygusuz T. HBsAg and anti-HBs seroprevalence in chronic hemodialysis patients. F Ü Med J Health Sci 2007;21 (2):55-57.
• 13. Ozer B, İnci M, Duran N, Sapan E, Alagoz GE, Köksaldı-Motor V. Comparison of HBV, HCV and HIV seropositivity in university hospital healthcare workers with hospital admissions. JCEI 2010; 27:46-9.
• 14. Eleftheriadis T, Liakopolos V, Leivaditis K, Antoniadi G, Stefanidis I. Infections in hemodialysis: a concise review.Part II:blood transmitted viral infections. Hippokratia 2011;15 (2):120-6.
• 15. Piskinpasa S, Akoglu H, Ozkayar N, Turgut D, Akyel F, Demir M, et al. Seroprevalance of the Hepatitis B and C in Patients with Chronic Kidney Disease without History of Renal Replacement Therapy. Turk Neph Dial Transpl 2013;22 (2):171-6.
• 16. Rabanal CPL, Zevallos JC, Cusato RC. Impact of hepatitis C in mortality in patients on hemodialysis. J Bras Nefrol 2010;32 (4):335-9.
• 17.Jakupi X, Mlakar J, Lunar MM et al. A Very Prevalence of Hepatitis C Virus Infection Among Patients Undergoing Hemodialysis in Kosovo: A Nationwide Study. BMC Nephrol 2018;19(1):304.
• 18. Kansay S, Sekhon J, Rana S. Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus Among Hemodialysis Patients in a Tertiary Care Teaching Hospital in a Developing Country. Indian J Sex Transm Dis AIDS 2019;40 (2):120-5.
• 19. Khokhar N, Alam AY, Naz F, Mahmud SN. Risk factors for hepatitis C virus infection in patients on long-term hemodialysis. J Coll Physicians Surg Pak 2005;32(4):326-8.
• 20. Afsar B, Elsurer R, Yilmaz Mİ. Hepatitis C infection and dialysis; an overview. Turk Neph Dial Transpl 2009;18(3):152-9.
• 21. Bozkurt I, Aygen B, Yildiz O, Gokahmetoglu S. The frequency and epidemiological characteristics of hepatitis C virus infection in hemodialysis patients in our region. Clinical journal 2011;24(3):167-72.
• 22.Demirpençe O, Tezcan SI, Degirmen E, Mert D, Gumuş A, Çelen MK. Hepatitis and HIV Serology Results in People Applying to Batman State Hospital. J Viral Hepat 2012;18(1):6-10.
• 23.Vigneau C, Guiard-Schmid JB, Tourret J et al. The clinical characteristics of HIV infected patients receiving dialysis in France between 1997 and 2002. Kidney Int 2005;67(4):1509-14.
• 24. Zahedi MJ, Moghaddam SD, Alavian SM, Dalili M. Seroprevalence of Hepatitis Viruses B, C, D and HIV Infection Among Hemodialysis Patients in Kerman Province.South-East Iran Hepat Mon 2012; 12(5):339-43.